

Adjuvant use of drug

Robertson CN, Paulson DF. Radical surgery versus radiation therapy in early prostatic carcinoma. *Acta Oncol* 1991;**30**:239–42.

Kanis JA, Powles T, Paterson AH, McCloskey EV, Ashley S. Clodronate decreases the frequency of skeletal metastases in women with breast cancer. *Bone* 1996;**19**:663–7.

Brincker H, Westin J, Abildgaard N, Gimsing P, Turesson I, Hedenus M, *et al.* Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish co-operative study group. *Br J Haematol* 1998;**101**:280–6.

Saarto T, Blomqvist C, Virkkunen P, Elomaa I. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. *J Clin Oncol* 2001;**19**:10–17.

Powles T, Paterson S, Kanis JA, McCloskey E, Ashley S, Tidy A, *et al.* Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. *J Clin Oncol* 2002;**20**:3219–24.

Atula S, Powles T, Paterson A, McCloskey E, Nevalainen J, Kanis J. Extended safety profile of oral clodronate after long-term use in primary breast cancer patients. *Drug Safety* 2003;**26**:661–71.

Saarto T, Vehmanen L, Virkkunen P, Blomqvist C. Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. *Acta Oncol* 2004;**43**:650–6.

Saarto T, Taube T, Blomqvist C, Vehmanen L, Elomaa I. Three-year oral clodronate treatment does not impair mineralization of newly formed bone – a histomorphometric study. *Calcif Tiss Int* 2005;**77**:84–90.

Mystakidou K, Katsouda E, Parpa E, Kelekis A, Galanos A, Vlahos L. Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline. *Medical Oncol* 2005;**22**:195–201.

Leppa S, Saarto T, Vehmanen L, Blomqvist C, Elomaa I. Clodronate treatment influences MMP-2 associated outcome in node positive breast cancer. *Breast Cancer Res Treatment* 2005;**90**:117–25.

Powles T, Paterson A, McCloskey E, Schein P, Scheffler B, Tidy A, *et al.* Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. [Erratum appears in *Breast Cancer Res* 2006;**8**:406]. *Breast Cancer Res* 2006;**8**:R13.

Ellis GK, Bone HG, Chlebowski R, Paul D, Spadafora S, Smith J, *et al.* Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. *J Clin Oncol* 2008;**26**:4875–82.

Kristensen B, Ejlersen B, Mouridsen HT, Jensen MB, Andersen J, Bjerregaard B, *et al.* Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. *Acta Oncol* 2008;**47**:740–6.

Ellis GK, Bone HG, Chlebowski R, Paul D, Spadafora S, Fan M, *et al.* Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study. *Breast Cancer Res Treat* 2009;**118**:81–7.

Gnant M. The evolving role of zoledronic acid in early breast cancer. *Onco Targets Ther* 2009;**2**:95–104.

Dearnaley DP, Mason MD, Parmar MK, Sanders K, Sydes M. Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials. *Lancet Oncol* 2009;**10**:872–6.

McCloskey E, Paterson A, Kanis J, Tahtela R, Powles T. Effect of oral clodronate on bone mass, bone turnover and subsequent metastases in women with primary breast cancer. *Eur J Cancer* 2010;**46**:558–65.

Kim SH, Lim SK, Hahn JS. Effect of pamidronate on new vertebral fractures and bone mineral density in patients with malignant lymphoma receiving chemotherapy. *Am J Med* 2004;**116**:524–8.

Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, Grampp S, Kaessmann H, Schmid M, *et al.* Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. *J Clin Oncol* 2007;**25**:820–8.

Hershman DL, McMahon DJ, Crew KD, Cremers S, Irani D, Cucchiara G, *et al.* Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. *J Clin Oncol* 2008;**26**:4739–45.

Comparing doses of radiotherapy

Roos DE, Turner SL, O'Brien PC, Smith JG, Spry NA, Burmeister BH, *et al.* Randomized trial of 8 Gy in 1 versus 20 Gy in 5 fractions of radiotherapy for neuropathic pain due to bone metastases (Trans-Tasman Radiation Oncology Group, TROG 96.05). *Radiother Oncol* 2005;**75**:54–63.

Madsen EL. Painful bone metastasis: efficacy of radiotherapy assessed by the patients: a randomized trial comparing 4 Gy X 6 versus 10 Gy X 2. *Int J Radiat Oncol Biol Phys* 1983;**9**:1775–9.

Jeremic B, Shibamoto Y, Acimovic L, Milicic B, Milisavljevic S, Nikolic N, *et al.* A randomized trial of three single-dose radiation therapy regimens in the treatment of metastatic bone pain. *Int J Radiat Oncol Biol Phys* 1998;**42**:161–7.

Kaasa S, Brenne E, Lund JA, Fayers P, Falkmer U, Holmberg M, *et al.* Prospective randomised multicenter trial on single fraction radiotherapy (8 Gy x 1) versus multiple fractions (3 Gy x 10) in the treatment of painful bone metastases. *Radiother Oncol* 2006;**79**:278–84.

Price P, Hoskin PJ, Easton D, Austin D, Palmer SG, Yarnold JR. Prospective randomised trial of single and multifraction radiotherapy schedules in the treatment of painful bony metastases. *Radiother Oncol* 1986;**6**:247–55.

Okawa T, Kita M, Goto M, Nishijima H, Miyaji N. Randomized prospective clinical study of small, large and twice-a-day fraction radiotherapy for painful bone metastases. *Radiother Oncol* 1988;**13**:99–104.

Cole DJ. A randomized trial of a single treatment versus conventional fractionation in the palliative radiotherapy of painful bone metastases. *Clin Oncol (R Coll Radiol)* 1989;**1**:59–62.

Nielsen OS, Bentzen SM, Sandberg E, Gadeberg CC, Timothy AR. Randomized trial of single dose versus fractionated palliative radiotherapy of bone metastases. *Radiother Oncol* 1998;**47**:233–40.

Roos DE, O'Brien PC, Smith JG, Spry NA, Hoskin PJ, Burmeister BH, *et al.* A role for radiotherapy in neuropathic bone pain: preliminary response rates from a prospective trial (Trans-tasman radiation oncology group, TROG 96.05).[Erratum appears in *Int J Radiat Oncol Biol Phys* 2000;**47**:545]. *Int J Radiat Oncol Biol Phys* 2000;**46**:975–81.

Ozsaran Z, Yalman D, Anacak Y, Esassolak M, Haydaroglu A. Palliative radiotherapy in bone metastases: results of a randomized trial comparing three fractionation schedules. *Juon B* 2001;**6**:43–8.

Sarkar SK, Sarkar S, Pahari B, Majumdar D. Multiple and single fraction palliative radiotherapy in bone secondaries – a prospective study. *Indian J Radiol Imag* 2002;**12**:281–4.

van den Hout WB, van der Linden YM, Steenland E, Wiggendaad RG, Kievit J, de Haes H, *et al.* Single-versus multiple-fraction radiotherapy in patients with painful bone metastases: cost–utility analysis based on a randomized trial. *J Natl Cancer Inst* 2003;**95**:222–9.

Badzio A, Senkus-Konefka E, Jereczek-Fossa BA, Adamska K, Fajndt S, Tesmer-Laskowska I, *et al.* [20 Gy in five fractions versus 8 Gy in one fraction in palliative radiotherapy of bone metastases. A multicenter randomized study.] *Nowotwory* 2003;**53**:261–4.

van der Linden YM, Lok JJ, Steenland E, Martijn H, van Houwelingen H, Marijnen CA, *et al.* Single fraction radiotherapy is efficacious: a further analysis of the Dutch Bone Metastasis Study controlling for the influence of retreatment. *Int J Radiat Oncol Biol Phys* 2004;**59**:528–37.

van der Linden YM, Steenland E, van Houwelingen HC, Post WJ, Oei B, Marijnen CA, *et al.* Patients with a favourable prognosis are equally palliated with single and multiple fraction radiotherapy: results on survival in the Dutch Bone Metastasis Study. *Radiother Oncol* 2006;**78**:245–53.

Manas A, Casas F, Ciria JP, Lopez C, Saez J, Palacios A, *et al.* Randomised study of single dose (8 Gy vs. 6 Gy) of analgesic radiotherapy plus zoledronic acid in patients with bone metastases. *Clin Transl Oncol* 2008;**10**:281–7.

Amouzegar-Hashemi F, Behrouzi H, Kazemian A, Zarpak B, Haddad P. Single versus multiple fractions of palliative radiotherapy for bone metastases: a randomized clinical trial in Iranian patients. *Curr Oncol* 2008;**15**:36–9.

Maranzano E, Trippa F, Casale M, Costantini S, Lupattelli M, Bellavita R, *et al.* 8Gy single-dose radiotherapy is effective in metastatic spinal cord compression: results of a phase III randomized multicentre Italian trial. *Radiother Oncol* 2009;**93**:174–9.

Meeuse JJ, van der Linden YM, van Tienhoven G, Gans RO, Leer JW, Reyners AK, *et al.* Efficacy of radiotherapy for painful bone metastases during the last 12 weeks of life: results from the Dutch Bone Metastasis Study. *Cancer* 2010;**116**:2716–25.

Atahan L, Yildiz F, Cengiz M, Kaplan B, Ozkan M, Yazici G, *et al.* Zoledronic acid concurrent with either high- or reduced-dose palliative radiotherapy in the management of the breast cancer patients with bone metastases: a phase IV randomised clinical study. *Support Care Cancer* 2010;**18**:691–8.

Bone Pain Trial Working Party. 8 Gy single fraction radiotherapy for the treatment of metastatic skeletal pain: randomised comparison with a multifraction schedule over 12 months of patient follow-up. *Radiother Oncol* 1999;**52**:111–21.

Roos DE, Davis SR, Turner SL, O'Brien PC, Spry NA, Burmeister BH, *et al.* Quality assurance experience with the randomised neuropathic bone pain trial (Trans-Tasman Radiation Oncology Group, 96.05). *Radiother Oncol* 2003;**67**:207–12.

Foro AP, Fontanals AV, Galceran JC, Lynd F, Latiesas XS, de Dios NR, *et al.* Randomized clinical trial with two palliative radiotherapy regimens in painful bone metastases: 30 Gy in 10 fractions compared with 8 Gy in single fraction. *Radiother Oncol* 2008;**89**:150–5.

Dose-ranging study

Thurlimann B, Morant R, Jungi WF, Radziwill A. Pamidronate for pain control in patients with malignant osteolytic bone disease: a prospective dose-effect study. *Support Care Cancer* 1994;**2**:61–5.

Groff L, Zecca E, De Conno F, Brunelli C, Boffi R, Panzeri C, *et al.* The role of disodium pamidronate in the management of bone pain due to malignancy. *Palliat Med* 2001;**15**:297–307.

Zhao X, Xu X, Guo L, Ragaz J, Guo H, Wu J, *et al.* Biomarker alterations with metronomic use of low-dose zoledronic acid for breast cancer patients with bone metastases and potential clinical significance. *Breast Cancer Res Treat* 2010;**124**:733–43.

Wu JSY, Wong R, Johnston M, Bezjak A, Whelan T. Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases. *Int J Radiat Oncol Biol Phys* 2003;**55**:594–605.

Daragon A, Peyron R, Serrurier D, Deshayes P. Treatment of hypercalcemia of malignancy with intravenous aminohydroxypropylidene bisphosphonate. Results of a stratified, double-blind, randomised two-month dose–response study. *Curr Ther Res Clin Exp* 1991;**50**:10–21.

Gallacher SJ, Ralston SH, Fraser WD, Dryburgh FJ, Cowan RA, Logue FC, *et al.* A comparison of low versus high dose pamidronate in cancer-associated hypercalcaemia. *Bone Miner* 1991;**15**:249–56.

Nussbaum SR, Younger J, Vandepol CJ, Gagel RF, Zubler MA, Chapman R, *et al.* Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages. *Am J Med* 1993;**95**:297–304.

Glover D, Lipton A, Keller A, Miller AA, Browning S, Fram RJ, *et al.* Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose-seeking study. *Cancer* 1994;**74**:2949–55.

Vinholes J, Guo CY, Purohit OP, Eastell R, Coleman RE. Metabolic effects of pamidronate in patients with metastatic bone disease. *Br J Cancer* 1996;**73**:1089–95.

Coleman RE, Purohit OP, Vinholes JJ, Zekri J. High dose pamidronate: clinical and biochemical effects in metastatic bone disease. *Cancer* 1997;**80**:S1686–90.

Cascinu S, Graziano F, Alessandrini P, Ligi M, Del Ferro E, Rossi D, *et al.* Different doses of pamidronate in patients with painful osteolytic bone metastases. *Support Care Cancer* 1998;**6**:139–43.

Coleman RE, Purohit OP, Black C, Vinholes JJ, Schlosser K, Huss H, *et al.* Double-blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease. *Ann Oncol* 1999;**10**:311–16.

Koeberle D, Bacchus L, Thuerlimann B, Senn HJ. Pamidronate treatment in patients with malignant osteolytic bone disease and pain: a prospective randomized double-blind trial. *Support Care Cancer* 1999;**7**:21–7.

Piffanelli A, Dafermou A, Giganti M, Colamussi P, Pizzocaro C, Bestagno M. Radionuclide therapy for painful bone metastases: an Italian multicentre observational study. *Q J Nucl Med* 2001;**45**:100–7.

Lipton A, Steger GG, Figueroa J, Alvarado C, Solal-Celigny P, Body JJ, *et al*. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. *J Clin Oncol* 2007;**25**:4431–7.

Generali D, Dovio A, Tampellini M, Tucci M, Tedoldi S, Torta M, *et al*. Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases. *Br J Cancer* 2008;**98**:1753–8.

Satoh T, Kimura M, Matsumoto K, Tabata K, Okusa H, Bessho H, *et al*. Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormone-naïve prostate carcinoma. *Cancer* 2009;**115**:3468–74.

Fizazi K, Bosserman L, Gao G, Skacel T, Markus R. Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial. *J Urol* 2009;**182**:509–15.

Fizazi K, Lipton A, Mariette X, Body JJ, Rahim Y, Gralow JR, *et al*. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. *J Clin Oncol* 2009;**27**:1564–71.

Gimsing P, Carlson K, Turesson I, Fayers P, Waage A, Vangsted A, *et al*. Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial. *Lancet Oncol* 2010;**11**:973–82.

Campbell-Baird C, Lipton A, Sarkeshik M, Ma H, Jun S. Incidence of acute phase adverse events following denosumab or intravenous bisphosphonates: results from a randomized, controlled phase II study in patients with breast cancer and bone metastases. *Commun Oncol* 2010;**7**:85–9.

Economic study

Laakso M, Lahtinen R, Virkkunen P, Elomaa I. Subgroup and cost–benefit analysis of the Finnish multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group. *Br J Haematol* 1994;**87**:725–9.

Gessner U, Koeberle D, Thuerlimann B, Bacchus L, Horisberger B. Economic analysis of terminal care for patients with malignant osteolytic bone disease and pain treated with pamidronate. *Support Care Cancer* 2000;**8**:115–22.

Dranitsaris G, Hsu T. Cost utility analysis of prophylactic pamidronate for the prevention of skeletal related events in patients with advanced breast cancer. *Support Care Cancer* 1999;**7**:271–9.

Dranitsaris G. Pamidronate for the prevention of skeletal-related events in multiple myeloma. What does the public think it is worth? *Int J Technol Assess Health Care* 1999;**15**:108–22.

Hillner BE, Weeks JC, Desch CE, Smith TJ. Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis. *J Clin Oncol* 2000;**18**:72–9.

Body J-J. Effectiveness and cost of bisphosphonate therapy in tumour bone disease. *Cancer* 2003;**97**:859–65.

Reed SD, Radeva JI, Glendenning GA, Saad F, Schulman KA. Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer. *J Urol* 2004;**171**:1537–42.

Reed SD, Radeva JI, Glendenning GA, Coleman RE, Schulman KA. Economic evaluation of zoledronic acid versus pamidronate for the prevention of skeletal-related events in metastatic breast cancer and multiple myeloma. *Am J Clin Oncol* 2005;**28**:8–16.

Slof J, Badia X, Lizan L, Bautista FJ, Echarri E, Hurle ADG, *et al.* Zoledronic acid versus pamidronate: cost minimisation in bone metastasis. *J Med Econ* 2005;**8**:1–12.

Malmberg I, Persson U, Ask A, Tennvall J, Abrahamsson PA. Painful bone metastases in hormone-refractory prostate cancer: economic costs of strontium-89 and/or external radiotherapy. *Urology* 1997;**50**:747–53.

Multiple myeloma patient group

Kraj M, Poglod R, Maj S, Pawlikowski J, Sokolowska U, Szczepanik J. [Long-term efficacy and safety of zoledronic acid compared with pamidronate in the treatment of myeloma bone disease.] *Acta Haematol Polon* 2004;**35**:227–41.

Delmas PD, Charhon S, Chapuy MC, Vignon E, Briancou D, Edouard C, *et al.* Long-term effects of dichloromethylene diphosphonate (Cl2MDP) on skeletal lesions in multiple myeloma. *Metab Bone Dis Relat Res* 1982;**4**:163–8.

Lahtinen R, Laakso M, Palva I, Virkkunen P, Elomaa I. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group. [Erratum appears in *Lancet* 1992;340(8832):1420]. *Lancet* 1992;**340**:1049–52.

Heim ME, Clemens MR, Queisser W, Pecherstorfer M, Boewer C, Herold M, *et al.* Prospective randomized trial of dichloromethylene bisphosphonate (clodronate) in patients with multiple myeloma requiring treatment. A multicenter study. *Onkologie* 1995;**18**:439–48.

Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, *et al.* Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. *N Engl J Med* 1996;**334**:488–93.

Berenson JR. Bisphosphonates in multiple myeloma. *Cancer* 1997;**80**:S1661–7.

McCloskey EV, MacLennan IC, Drayson MT, Chapman C, Dunn J, Kanis JA. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults. *Br J Haematol* 1998;**100**:317–25.

Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, *et al.* Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. *J Clin Oncol* 1998;**16**:593–602.

Terpos E, Palermos J, Tsonos K, Anargyrou K, Viniou N, Papassavas P, *et al.* Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma. *Eur J Haematol* 2000;**65**:331–6.

Fonseca R, Trendle MC, Leong T, Kyle RA, Oken MM, Kay NE, *et al.* Prognostic value of serum markers of bone metabolism in untreated multiple myeloma patients. *Br J Haematol* 2000;**109**:24–9.

McCloskey EV, Dunn JA, Kanis JA, MacLennan IC, Drayson MT. Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma. *Br J Haematol* 2001;**113**:1035–43.

Kraj M, Poglod R, Maj S, Pawlikowski J. [The effects of 8-year pamidronate treatment on skeletal morbidity in patients with advanced multiple myeloma.] *Nowotwory* 2004;**54**:570–7.

Aviles A, Nambo MJ, Neri N, Castaneda C, Cleto S, Huerta-Guzman J. Antitumour effect of zoledronic acid in previously untreated patients with multiple myeloma. *Med Oncol* 2007;**24**:227–30.

Terpos E, Berenson J, Cook RJ, Lipton A, Coleman RE. Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease. *Leukaemia* 2010;**24**:1043–9.

No relevant comparators

Mystakidou K, Katsouda E, Parpa E, Kouskouni E, Chondros C, Tsiatas ML, *et al.* A prospective randomized controlled clinical trial of zoledronic acid for bone metastases. *Am J Hospice Palliat Med* 2006;**23**:41–50.

Ausili-Cefaro G, Capirci C, Crivellari D, Fontana V, Mandoliti G, Olmi P, *et al.* Radiation therapy vs radiation therapy + pamidronate (Aredia™) in elderly patients with breast cancer and lytic bone metastases: a GROG-GIOGer randomized clinical trial. *Rays* 1999;**24**:49–52.

Wang RF, Zhang CL, Zhu SL, Zhu M. A comparative study of samarium-153-ethylenediaminetetramethylene phosphonic acid with pamidronate disodium in the treatment of patients with painful metastatic bone cancer. *Med Princ Pract* 2003;**12**:97–101.

van der Linden YM, Dijkstra SP, Vonk EJ, Marijnen CA, Leer JW, Dutch Bone Metastasis Study Group. Prediction of survival in patients with metastases in the spinal column: results based on a randomized trial of radiotherapy. *Cancer* 2005;**103**:320–8.

Michaelson MD, Kaufman DS, Kantoff P, Oh WK, Smith MR. Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer. *Cancer* 2006;**107**:530–5.

Lipton A, Cook RJ, Major P, Smith MR, Coleman RE. Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. *Oncologist* 2007;**12**:1035–43.

Lipton A, Steger GG, Figueroa J, Alvarado C, Solal-Celigny P, Body JJ, *et al.* Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. *Clin Cancer Res* 2008;**14**:6690–6.

No relevant interventions

Lewington VJ, McEwan AJ, Ackery DM, Bayly RJ, Keeling DH, Macleod PM, *et al.* A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. *Eur J Cancer* 1991;**27**:954–8.

Belch AR, Bergsagel DE, Wilson K, O'Reilly S, Wilson J, Sutton D, *et al.* Effect of daily etidronate on the osteolysis of multiple myeloma. *J Clin Oncol* 1991;**9**:1397–402.

Porter AT, McEwan AJ. Strontium-89 as an adjuvant to external beam radiation improves pain relief and delays disease progression in advanced prostate cancer: results of a randomized controlled trial. *Semin Oncol* 1993;**20**:38–43.

Niewald M, Tkocz HJ, Abel U, Scheib T, Walter K, Nieder C, *et al*. Rapid course radiation therapy vs. more standard treatment: a randomized trial for bone metastases. *Int J Radiat Oncol Biol Phys* 1996;**36**:1085–9.

Serafini AN, Houston SJ, Resche I, Quick DP, Grund FM, Ell PJ, *et al*. Palliation of pain associated with metastatic bone cancer using samarium-153 lexitronam: a double-blind placebo-controlled clinical trial. *J Clin Oncol* 1998;**16**:1574–81.

Pelger RC, Hamdy NA, Zwinderman AH, Nijeholt AA, Papapoulos SE. Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton. *Bone* 1998;**22**:403–8.

Sciuto R, Festa A, Pasqualoni R, Semprebene A, Rea S, Bergomi S, *et al*. Metastatic bone pain palliation with 89-Sr and 186-Re-HEDP in breast cancer patients. *Breast Cancer Res Treat* 2001;**66**:101–9.

Oosterhof GO, Roberts JT, de Reijke TM, Engelholm SA, Horenblas S, von der Maase H, *et al*. Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group. *Eur Urol* 2003;**44**:519–26.

Smeland S, Erikstein B, Aas M, Skovlund E, Hess SL, Fossa SD. Role of strontium-89 as adjuvant to palliative external beam radiotherapy is questionable: results of a double-blind randomized study. *Int J Radiat Oncol Biol Phys* 2003;**56**:1397–404.

Pistevou-Gompaki K, Kouloulis VE, Varveris C, Mystakidou K, Georgakopoulos G, Eleftheriadis N, *et al*. Radiotherapy plus either transdermal fentanyl or paracetamol and codeine for painful bone metastases: a randomised study of pain relief and quality of life. *Curr Med Res Opin* 2004;**20**:159–63.

Wardley A, Davidson N, Barrett-Lee P, Hong A, Mansi J, Dodwell D, *et al*. Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. *Br J Cancer* 2005;**92**:1869–76.

Harstell WF, Scott CB, Bruner DW, Scarantino CW, Ivker RA, Roach IM, *et al*. Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. *J Natl Cancer Inst* 2005;**97**:798–804.

Clemons MJ, Dranitsaris G, Ooi WS, Yogendran G, Sukovic T, Wong BYL, *et al*. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. *J Clin Oncol* 2006;**24**:4895–900.

Djabelek-Macias M, Niewska I, Ochman M, Odziejczyk A, Zebrowski J, Piwkowski P. The effects of radioisotope therapy and radiotherapy in subjects with breast cancer with bone metastases. *Nucl Med Rev Cent East Eur* 2006;**9**:138–43.

Hamouda WE, Roshdy W, Teema M. Single versus conventional fractionated radiotherapy in the palliation of painful bone metastases. *Gulf J Oncol* 2007;**1**:35–41.

Elomaa I, Blomqvist C, Grohn P, Porkka L, Kairento AL, Selander K, *et al*. Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases. *Lancet* 1983;**1**:146–9.

Tian JH, Zhang JM, Hou QT, Oyang QH, Wang JM, Luan ZS, *et al.* Multicentre trial on the efficacy and toxicity of single-dose samarium-153-ethylene diamine tetramethylene phosphonate as a palliative treatment for painful skeletal metastases in China. *Eur J Nucl Med* 1999;**26**:2–7.

Attal M, Harousseau JL, Leyvraz S, Doyen C, Hulin C, Benboubker L, *et al.* Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. *Blood* 2006;**108**:3289–94.

No relevant outcomes

Coleman RE. Preliminary results of the use of urinary excretion of pyridinium crosslinks for monitoring metastatic bone disease. *Br J Cancer* 1992;**65**:766–8.

Pentikainen PJ, Elomaa I, Nurmi A-K, Karkkainen S. Pharmacokinetics of clodronate in patients with metastatic breast cancer. *Int J Clin Pharmacol Ther Toxicol* 1989;**27**:223–8.

Cheung WK, Brunner L, Schoenfeld S, Knight R, Seaman J, Brox A, *et al.* Pharmacokinetics of pamidronate disodium in cancer patients after a single intravenous infusion of 30-, 60- or 90-mg dose over 4 or 24 hours. *Am J Ther* 1994;**1**:228–35.

Kylmä T, Castrén-Kortekangas P, Seppänen J, Ylitalo P, Tammela TL. Effect of concomitant administration of clodronate and estramustine phosphate on their bioavailability in patients with metastasized prostate cancer. *Pharmacol Toxicol* 1996;**79**:157–60.

Schlosser K, Scigalla P. Biochemical markers as surrogates in clinical trials in patients with metastatic bone disease and osteoporosis. *Scand J Clin Lab Invest Suppl* 1997;**227**:21–8.

Ylitalo P, Holli K, Monkkonen J, Elo HA, Juhakoski A, Liukko-Sipi S, *et al.* Comparison of pharmacokinetics of clodronate after single and repeated doses. *Int J Clin Pharmacol Ther* 1999;**37**:294–300.

Kanis JA, McCloskey EV, Powles T, Paterson AH, Ashley S, Spector T. A high incidence of vertebral fracture in women with breast cancer. *Br J Cancer* 1999;**79**:1179–81.

Chen T, Berenson J, Vescio R, Swift R, Gilchick A, Goodin S, *et al.* Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. *J Clin Pharmacol* 2002;**42**:1228–36.

Lyubimova NV, Kushlinsky NE, Lichinitser MR, Schlosser K. Renal safety of intravenous ibandronic acid in breast cancer patients with metastatic bone disease. *Clin Drug Invest* 2003;**23**:707–16.

Weinfurt KP, Castel LD, Li Y, Timbie JW, Glendenning GA, Schulman KA. Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions. *Med Care* 2004;**42**:164–75.

Weinfurt KP, Li Y, Castel LD, Saad F, Timbie JW, Glendenning GA, *et al.* The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. *Ann Oncol* 2005;**16**:579–84.

Pecherstorfer M, Rivkin S, Body JJ, Diel I, Bergstrom B. Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: an open-label trial. *Clin Drug Invest* 2006;**26**:315–22.

Body JJ, Diel IJ, Tripathy D, Bergstrom B. Intravenous ibandronate does not affect time to renal function deterioration in patients with skeletal metastases from breast cancer: phase III trial results. *Eur J Cancer Care* 2006;**15**:299–302.

- Cook RJ, Coleman R, Brown J, Lipton A, Major P, Hei YJ, *et al.* Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. *Clin Cancer Res* 2006;**12**:3361–7.
- Body JJ, Facon T, Coleman RE, Lipton A, Geurs F, Fan M, *et al.* A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. *Clin Cancer Res* 2006;**12**:1221–8.
- von Moos R, Caspar CB, Thurlimann B, Angst R, Inauen R, Greil R, *et al.* Renal safety profiles of ibandronate 6 mg infused over 15 and 60 min: a randomised, open-label study. *Ann Oncol* 2008;**19**:1266–70.
- von Moos R, Caspar CB, Steiner R, Angst R, Inauen R, Schmieding K, *et al.* Long-term renal safety profile of ibandronate 6 mg infused over 15 minutes. *Onkologie* 2010;**33**:447–50.
- Markkula R, Repo H, Leirisalo M, Blomqvist C, Elomaa I. Effect of dichloromethylene diphosphonate (Cl2MDP) on immune function in breast cancer patients with bone metastases. *Cancer Immunol Immunother* 1983;**15**:159–61.
- Elomaa I, Blomqvist C, Porkka L, Lamberg-Allardt C, Borgström GH. Treatment of skeletal disease in breast cancer: a controlled clodronate trial. *Bone* 1987;**8**(Suppl. 1):53–6.
- Martinez ME, Pastrana P, Sanchez-Cabezudo MJ, Jariego C, Del Campo MT. Effect of clodronate on calcidiol serum levels in women with breast cancer. *Calcif Tiss Int* 1997;**61**:148–50.
- Smith MR, Cook RJ, Coleman R, Brown J, Lipton A, Major P, *et al.* Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer. *Urology* 2007;**70**:315–19.
- Body JJ, Lichinitser M, Tjulandin S, Garnero P, Bergstrom B. Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases. [Erratum appears in *Ann Oncol* 2008;**19**:601]. *Ann Oncol* 2007;**18**:1165–71.
- Hirsh V, Major PP, Lipton A, Cook RJ, Langer CJ, Smith MR, *et al.* Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. *J Thoracic Oncol* 2008;**3**:228–36.
- Jung A, Chantraine A, Donath A, van Ouwenaller C, Turnill D, Mermillod B, *et al.* Use of dichloromethylene diphosphonate in metastatic bone disease. *N Engl J Med* 1983;**308**:1499–501.
- Conte N, Di Virgilio R, Da Rin G, Roiter I, Pavan P, Legovini P, *et al.* Clodronate treatment increases serum osteocalcin in normocalcemic osteolytic bone metastases. *Oncology* 1991;**48**:54–7.
- Redalieu E, Coleman JM, Chan K, Seaman J, Degen PH, Flesch G, *et al.* Urinary excretion of aminohydroxypropylidene bisphosphonate in cancer patients after single intravenous infusions. *J Pharmaceut Sci* 1993;**82**:665–7.
- Clemens MR, Fessele K, Heim ME. Multiple myeloma: effect of daily dichloromethylene bisphosphonate on skeletal complications. *Ann Haematol* 1993;**66**:141–6.
- Vinholes JJ, Purohit OP, Abbey ME, Eastell R, Coleman RE. Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease. *Ann Oncol* 1997;**8**:1243–50.

Vinholes J, Coleman RE, Lacombe D, Rose C, Tubiana-Hulin M, Bastit P, *et al.* Assessment of bone response to systemic therapy in an EORTC trial: preliminary experience with the use of collagen cross-link excretion. *Br J Cancer* 1999;**80**:221–8.

Ryan CW, Huo D, Bylow K, Demers LM, Stadler WM, Henderson TO, *et al.* Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid. *BJU Int* 2007;**100**:70–5.

Not a relevant patient group

McLachlan SA, Cameron D, Murray R, Tripathy D, Bergstrom B. Safety of oral ibandronate in the treatment of bone metastases from breast cancer: long-term follow-up experience. *Clin Drug Invest* 2006;**26**:43–8.

Taube T, Kylmala T, Lamberg-Allardt C, Tammela TL, Elomaa I. The effect of clodronate on bone in metastatic prostate cancer. Histomorphometric report of a double-blind randomised placebo-controlled study. *Eur J Cancer* 1994;**30A**:751–8.

Nesković-Konstantinović Z, Mitrović L, Petrović J, Stamatović L, Ristović Z. Treatment of tumour-induced hypercalcaemia in advanced breast cancer patients with three different doses of disodium pamidronate adapted to the initial level of calcaemia. *Support Care Cancer* 1995;**3**:422–4.

Teshima T, Inoue T, Inoue T, Ikeda H, Murayama S, Yamazaki H, *et al.* Symptomatic relief for patients with osseous metastasis treated with radiation and methylprednisolone: a prospective randomized study. *Radiat Med* 1996;**14**:185–8.

Rizzoli R, Forni M, Schaad MA, Slosman DO, Sappino AP, Garcia J, *et al.* Effects of oral clodronate on bone mineral density in patients with relapsing breast cancer. *Bone* 1996;**18**:531–7.

Elomaa I, Risteli L, Laakso M, Lahtinen R, Virkkunen P, Risteli J. Monitoring the action of clodronate with type I collagen metabolites in multiple myeloma. *Eur J Cancer* 1996;**32A**:1166–70.

van Holten-Verzantvoort AT, Hermans J, Beex LV, Blijham G, Cleton FJ, van Eck-Smit BC, *et al.* Does supportive pamidronate treatment prevent or delay the first manifestation of bone metastases in breast cancer patients? *Eur J Cancer* 1996;**32A**:450–4.

Vinholes J, Guo CY, Purohit OP, Eastell R, Coleman RE. Evaluation of new bone resorption markers in a randomised comparison of pamidronate or clodronate for hypercalcaemia of malignancy. *J Clin Oncol* 1997;**15**:131–8.

Diel IJ, Solomayer EF, Costa SD, Gollan C, Goerner R, Wallwiener D, *et al.* Reduction in new metastases in breast cancer with adjuvant clodronate treatment. *N Engl J Med* 1998;**339**:357–63.

Mardiak J, Bohunicky L, Chovanec J, Salek T, Koza I. Adjuvant clodronate therapy in patients with locally advanced breast cancer – long term results of a double blind randomized trial. Slovak Clodronate Collaborative Group. *Neoplasma* 2000;**47**:177–80.

Musto P, Falcone A, Sanpaolo G, Bodenizza C, Cascavilla N, Melillo L, *et al.* Pamidronate reduces skeletal events but does not improve progression-free survival in early-stage untreated myeloma: results of a randomised trial. *Leuk Lymph* 2003;**44**:1545–8.

Theriault RL. Strategies to prevent chemotherapy-induced bone loss in women with breast cancer. *Clin Breast Cancer* 2005;**5**:S63–70.

Fuleihan GEH, Salamoun M, Mourad YA, Chehal A, Salem Z, Mahfoud Z, *et al.* Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomized controlled trial. *J Clin Endocrinol Metab* 2005;**90**:3209–14.

Mitsiades CS, Bogdanos J, Karamanolakis D, Milathianakis C, Dimopoulos T, Koutsilieris M. Randomized controlled clinical trial of a combination of somatostatin analogue and dexamethasone plus zoledronate vs. zoledronate in patients with androgen ablation-refractory prostate cancer. *Anticancer Res* 2006;**26**:3693–700.

Mason MD, Sydes MR, Glaholm J, Langley RE, Huddart RA, Sokal M, *et al.* Oral sodium clodronate for nonmetastatic prostate cancer – results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873). *J Natl Cancer Inst* 2007;**99**:765–76.

Loblaw DA, Wu JS, Kirkbride P, Panzarella T, Smith K, Aslanidis J, *et al.* Pain flare in patients with bone metastases after palliative radiotherapy – a nested randomized control trial. *Support Care Cancer* 2007;**15**:451–5.

Brufsky A, Harker WG, Beck JT, Carroll R, Tan-Chiu E, Seidler C, *et al.* Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. *J Clin Oncol* 2007;**25**:829–36.

Brufsky AM. Managing bone loss in women with early-stage breast cancer receiving aromatase inhibitors. *Clin Breast Cancer* 2007;**8**:S22–34.

Diel IJ, Jaschke A, Solomayer EF, Gollan C, Bastert G, Sohn C, *et al.* Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. *Ann Oncol* 2008;**19**:2007–11.

Lester JE, Dodwell D, Purohit OP, Gutcher SA, Ellis SP, Thorpe R, *et al.* Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. *Clin Cancer Res* 2008;**14**:6336–42.

Musto P, Petrucci MT, Bringhen S, Guglielmelli T, Caravita T, Bongarzone V, *et al.* A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma. [Erratum appears in *Cancer* 2008;**113**:2835]. *Cancer* 2008;**113**:1588–95.

Brufsky A, Bundred N, Coleman R, Lambert-Falls R, Mena R, Hadji P, *et al.* Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. *Oncologist* 2008;**13**:503–14.

Bundred NJ, Campbell ID, Davidson N, DeBoer RH, Eidtmann H, Monnier A, *et al.* Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results. *Cancer* 2008;**112**:1001–10.

Brufsky AM, Bosserman LD, Caradonna RR, Haley BB, Jones CM, Moore HC, *et al.* Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. *Clin Breast Cancer* 2009;**9**:77–85.

Eidtmann H, de Boer R, Bundred N, Llombart-Cussac A, Davidson N, Neven P, *et al.* Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. *Ann Oncol* 2010;**21**:2188–94.

Morgan GJ, Davies FE, Gregory WM, Cocks K, Bell SE, Szubert AJ, *et al.* First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. *Lancet* 2010;**376**:1989–99.

Not a required dose used

van Holten-Verzantvoort AT, Bijvoet OL, Cleton FJ, Hermans J, Kroon HM, Harinck HI, *et al.* Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment. *Lancet* 1987;**2**:983–5.

Canfield RE, Siris ES, Jacobs TP. Dichloromethylene diphosphonate action in hematologic and other malignancies. *Bone* 1987;**8**(Suppl. 1):57–62.

Cleton FJ, van Holten-Verzantvoort AT, Bijvoet OL. Effect of long-term bisphosphonate treatment on morbidity due to bone metastases in breast cancer patients. *Recent Results Cancer Res* 1989;**116**:73–8.

Dodwell DJ, Howell A, Ford J. Reduction in calcium excretion in women with breast cancer and bone metastases using the oral bisphosphonate pamidronate. *Br J Cancer* 1990;**61**:123–5.

van Holten-Verzantvoort AT, Zwinderman AH, Aaronson NK, Hermans J, van Emmerik B, van Dam FS, *et al.* The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer. *Eur J Cancer* 1991;**27**:544–9.

Martoni A, Guaraldi M, Camera P, Biagi R, Marri S, Beghe F, *et al.* Controlled clinical study on the use of dichloromethylene diphosphonate in patients with breast carcinoma metastasizing to the skeleton. *Oncology* 1991;**48**:97–101.

Francini G, Gonnelli S, Petrioli R, Conti F, Paffetti P, Gennari C. Treatment of bone metastases with dichloromethylene bisphosphonate. *J Clin Oncol* 1992;**10**:591–8.

van Holten-Verzantvoort AT, Kroon HM, Bijvoet OL, Cleton FJ, Beex LV, Blijham G, *et al.* Palliative pamidronate treatment in patients with bone metastases from breast cancer. *J Clin Oncol* 1993;**11**:491–8.

Conte PF, Giannesi PG, Latreille J, Mauriac L, Koliren L, Calabresi F, *et al.* Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: a randomized, multicenter phase III trial. *Ann Oncol* 1994;**5**(Suppl. 7):41–4.

Conte PF, Latreille J, Mauriac L, Calabresi F, Santos R, Campos D, *et al.* Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group. *J Clin Oncol* 1996;**14**:2552–9.

Giordani S, Sapio A, De Pasquale A, Mariano P, Versari R, Romano D. A randomized study on ‘prophylactic’ use of disodium pamidronate in breast cancer patients (bcps) with bone metastasis at high risk (HR) of complication: the experience of an ‘oncological hospital at home’ (OHH). *Ann Oncol* 1996;**7**(Suppl. 5):24.

Ernst DS, Brasher P, Hagen N, Paterson AH, MacDonald RN, Bruera E. A randomized, controlled trial of intravenous clodronate in patients with metastatic bone disease and pain. *J Pain Symptom Manage* 1997;**13**:319–26.

Coleman RE, Houston S, Purohit OP, Rubens RD, Kandra A, Ford J. A randomised phase II study of oral pamidronate for the treatment of bone metastases from breast cancer. *Eur J Cancer* 1998;**34**:820–4.

Hultborn R, Gundersen S, Ryden S, Holmberg E, Carstensen J, Wallgren UB, *et al.* Efficacy of pamidronate in breast cancer with bone metastases: a randomised, double-blind placebo-controlled multicenter study. *Anticancer Res* 1999;**19**:3383–92.

Kraj M, Poglod R, Pawlikowski J, Maj S, Nasilowska B. [Effect of pamidronate on skeletal morbidity in myelomatosis. Part 1. The results of the first 12 months of pamidronate therapy.] *Acta Pol Pharm* 2000;**57**:113–16.

Menssen HD, Sakalova A, Fontana A, Herrmann Z, Boewer C, Facon T, *et al.* Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma. *J Clin Oncol* 2002;**20**:2353–9.

Terpos E, Viniou N, de la Fuente J, Meletis J, Voskaridou E, Karkantaris C, *et al.* Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma. *Eur J Haematol* 2003;**70**:34–42.

Non-randomised controlled trials: reviews

Awan AM, Weichselbaum RR. Palliative radiotherapy. *Hematol Oncol Clin North Am* 1990;**4**:1169–81.

Delmas PD. The use of clodronate in multiple myeloma. *Bone* 1991;**12**(Suppl. 1):31–4.

Paterson AH, Ernst DS, Powles TJ, Ashley S, McCloskey EV, Kanis JA. Treatment of skeletal disease in breast cancer with clodronate. *Bone* 1991;**12**(Suppl. 1):25–30.

Clarke NW, McClure J, George NJ. Disodium pamidronate identifies differential osteoclastic bone resorption in metastatic prostate cancer. *Br J Urol* 1992;**69**:64–70.

Burgers JM. Experience of the EORTC Radiotherapy/Chemotherapy Group in osteosarcoma trials. *Cancer Treat Res* 1993;**62**:173–5.

Porter AT. Strontium-89 (Metastron) in the treatment of prostate cancer metastatic to bone. *Eur Urol* 1994;**26**:20–5.

Bos SD. An overview of current clinical experience with strontium-89 (Metastron). *Prostate* 1994;**24**:23–6.

Hoskin PJ. Radiotherapy in the management of bone pain. *Clin Orthop Relat Res* 1995;**312**:105–19.

Harvey HA, Lipton A. The role of bisphosphonates in the treatment of bone metastases – the U.S. experience. *Support Care Cancer* 1996;**4**:213–17.

Diener KM. Bisphosphonates for controlling pain from metastatic bone disease. *Am J Health Syst Pharm* 1996;**53**:1917–27.

Gaze MN, Kelly CG, Kerr GR, Cull A, Cowie VJ, Gregor A, *et al.* Pain relief and quality of life following radiotherapy for bone metastases: a randomised trial of two fractionation schedules. *Radiother Oncol* 1997;**45**:109–16.

Adami S. Bisphosphonates in prostate carcinoma. *Cancer* 1997;**80**:1674–9.

Lipton A. Bisphosphonates and breast carcinoma. *Cancer* 1997;**80**:1668–73.

Berenson JR. The efficacy of pamidronate disodium in the treatment of osteolytic lesions and bone pain in multiple myeloma. *Rev Contemp Pharmacother* 1998;**9**:195–203.

Paterson AHG. The emerging role of bisphosphonates in the prevention of bone metastases. *Trends Endocrinol Metab* 1999;**10**:24–9.

Yoneda T, Michigami T, Yi B, Williams PJ, Niewolna M, Hiraga T. Use of bisphosphonates for the treatment of bone metastasis in experimental animal models. *Cancer Treat Rev* 1999;**25**:293–9.

Serafini AN. Samarium Sm-153 lexidronam for the palliation of bone pain associated with metastases. *Cancer* 2000;**88**:S2934–9.

Ripamonti C, Fulfaro F. Malignant bone pain: pathophysiology and treatments. *Curr Rev Pain* 2000;**4**:187–96.

Berenson JR. Myeloma – the therapeutic challenge. *Med Klin* 2000;**95**:19–21.

Major PP, Coleman RE. Zoledronic acid in the treatment of hypercalcemia of malignancy: results of the international clinical development program. *Semin Oncol* 2001;**28**:S17–24.

Coleman RE, Seaman JJ. The role of zoledronic acid in cancer: clinical studies in the treatment and prevention of bone metastases. *Semin Oncol* 2001;**28**:S11–16.

Djulfbegovic B, Wheatley K, Ross J, Clark O, Bos G, Goldschmidt H, *et al*. Bisphosphonates in multiple myeloma. *Cochrane Database Syst Rev* 2001;**4**:CD003188.

Gralow JR. The role of bisphosphonates as adjuvant therapy for breast cancer. *Curr Oncol Rep* 2001;**3**:506–15.

Jeremic B. Single fraction external beam radiation therapy in the treatment of localised metastatic bone pain. A review. *J Pain Symptom Manage* 2001;**22**:1048–58.

Coleman RE. Efficacy of zoledronic acid and pamidronate in breast cancer patients: a comparative analysis of randomised phase III trials. *Am J Clin Oncol* 2002;**25**:S25–31.

Wong R, Wiffen PJ. Bisphosphonates for the relief of pain secondary to bone metastases. *Cochrane Database Syst Rev* 2002;**2**:CD002068.

Pavlakakis N, Stockler M. Bisphosphonates for breast cancer. *Cochrane Database Syst Rev* 2002;**1**:CD003474.

Saad F. Zoledronic acid significantly reduces pathologic fractures in patients with advanced-stage prostate cancer metastatic to bone. *Clin Prostate Cancer* 2002;**1**:145–52.

Lipton A, Small E, Saad F, Gleason D, Gordon D, Smith M, *et al*. The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. *Cancer Invest* 2002;**20**:45–54.

Jantunen E. Bisphosphonate therapy in multiple myeloma: past, present, future. *Eur J Haematol* 2002;**69**:257–64.

Hotte SJ, Weibert KE, Major PP. Zoledronic acid: an overview of its current and potential benefits in patients with malignancy. *Today Ther Trends J New Dev* 2002;**20**:197–219.

Rosen LS. Efficacy and safety of zoledronic acid in the treatment of bone metastases associated with lung cancer and other solid tumours. *Semin Oncol* 2002;**29**:28–32.

Ibrahim A, Scher N, Williams G, Sridhara R, Li N, Chen G, *et al*. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases. *Clin Cancer Res* 2003;**9**:2394–9.

Heffner J, Lonial S. Breakthroughs in the management of multiple myeloma. *Drugs* 2003;**63**:1621–36.

Kirby RS. Zoledronic acid: a new advance in managing skeletal events in prostate cancer. *BJU Int* 2003;**91**:464–5.

Kumar A, Loughran T, Alsina M, Durie BGM, Djulbegovic B. Management of multiple myeloma: a systematic review and critical appraisal of published studies. *Lancet Oncol* 2003;**4**:293–304.

Lipton A, Colombo-Berra A, Bukowski RM, Rosen L, Zheng M, Urbanowitz G. Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid. *Clin Cancer Res* 2004;**10**:S6397–403.

Dando TM, Wiseman LR. Clodronate: a review of its use in the prevention of bone metastases and the management of skeletal complications associated with bone metastases in patients with breast cancer. *Drugs Aging* 2004;**21**:949–62.

Tripathy D. Oral daily ibandronate: an effective and convenient therapy for skeletal complications in metastatic breast cancer. *Eur J Cancer Suppl* 2004;**2**:17–20.

Diel IJ. Ibandronate: a well-tolerated intravenous and oral treatment for metastatic bone disease. *Eur J Cancer Suppl* 2004;**2**:13–16.

Saad F, Schulman CC. Role of bisphosphonates in prostate cancer. *Eur Urol* 2004;**45**:26–34.

Gralow J. Evolving role of bisphosphonates in women undergoing treatment for localized and advanced breast cancer. *Clin Breast Cancer* 2005;**5**:S54–62.

Michaelson MD, Smith MR. Bisphosphonates for treatment and prevention of bone metastases. *J Clin Oncol* 2005;**23**:8219–24.

Saad F, Lipton A. Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers. *BJU Int* 2005;**96**:964–9.

Burkinshaw R, Coleman R. Bisphosphonates as adjuvant therapy for breast cancer. *J Womens Health* 2006;**2**:115–26.

Berry S, Waldron T, Winquist E, Lukka H. The use of bisphosphonates in men with hormone-refractory prostate cancer: a systematic review of randomised trials. *Can J Urol* 2006;**13**:3180–8.

Cameron D, Fallon M, Diel I. Ibandronate: its role in metastatic breast cancer. *Oncologist* 2006;**11**(Suppl. 1):27–33.

Yuen KK, Shelley M, Sze WM, Wilt T, Mason MD. Bisphosphonates for advanced prostate cancer. *Cochrane Database Syst Rev* 2006;**4**:CD006250.

Body J-J. Bisphosphonates in advanced malignant disease. *Clin Rev Bone Min Metab* 2007;**5**:172–7.

Burkinshaw R, Thorpe H, Coleman R. Bisphosphonates and prevention of metastases: The AZURE study. *Breast Cancer Online* 2007;**10**:e21.

Coleman RE. Emerging strategies in bone health management for the adjuvant patient. *Semin Oncol* 2007;**34**:S11–16.

Saad F. Should patients with prostate cancer without bone metastases receive sodium clodronate? Commentary. *Nat Clin Pract Urol* 2007;**4**:584–5.

Wu S, Dahut WL, Gulley JL. The use of bisphosphonates in cancer patients. *Acta Oncol* 2007;**46**:581–91.

Coleman R. Potential use of bisphosphonates in the prevention of metastases in early-stage breast cancer. *Clin Breast Cancer* 2007;**7**:S29–35.

Lipton A. Efficacy and safety of intravenous bisphosphonates in patients with bone metastases caused by metastatic breast cancer. *Clin Breast Cancer* 2007;**7**:S14–20.

Luftner D, Henschke P, Possinger K. Clinical value of bisphosphonates in cancer therapy. *Anticancer Res* 2007;**27**:1759–68.

Saad F, Sternberg CN. Multidisciplinary management of bone complications in prostate cancer and optimising outcomes of bisphosphonate therapy. *Nat Clin Pract Urol* 2007;**4**:S3–13.

Hussein MA. Multiple myeloma: most common end-organ damage and management. *J Natl Compr Canc Netw* 2007;**5**:170–8.

Lipton A. Treatment of bone metastases and bone pain with bisphosphonates. *Support Cancer Ther* 2007;**4**:92–100.

Brandao CMR, Lima MG, Da Silva AL, Silva GD, Guerra J, De Assis AF. [Treatment of postmenopausal osteoporosis in women: a systematic review.] *Cad Saude Publica* 2008;**24**:S592–606.

Dhillon S, Lyseng-Williamson KA. Zoledronic acid: a review of its use in the management of bone metastases of malignancy. *Drugs* 2008;**68**:507–34.

Burkiewicz JS, Scarpace SL, Bruce SP. Denosumab in osteoporosis and oncology. *Ann Pharmacother* 2009;**43**:1445–55.

Husaini D, Wheatley-Price D, Clemons D, Shepherd FA. Prevention and management of bone metastases in lung cancer: a review. *J Thorac Oncol* 2009;**4**:251–9.

Miller K, Stenzl A, Tombal B. Advances in the therapy of prostate cancer-induced bone disease: current insights and future perspectives on the RANK/RANKL pathways. *Eur Urol Suppl* 2009;**8**:747–52.

Machado M, Cruz LS, Tannus G, Fonseca M. Efficacy of clodronate, pamidronate, and zoledronate in reducing morbidity and mortality in cancer patients with bone metastasis: a meta-analysis of randomised clinical trials. *Clin Ther* 2009;**31**:962–79.

Mhaskar R, Redzepovic J, Wheatley K, Clark OA, Miladinovic B, Glasmacher A, et al. Bisphosphonates in multiple myeloma. *Cochrane Database Syst Rev* 2010;**3**:CO003188.

Diel IJ. Bisphosphonates in breast cancer patients with bone metastases. *Breast Care* 2010;**5**:306–11.

Silver DS. Denosumab reduces the incidence of new vertebral fractures in men with prostate cancer. *Curr Osteoporos Rep* 2010;**8**:1–3.

Coleman R. The use of bisphosphonates in cancer treatment. *Ann N Y Acad Sci* 2011;**1218**:3–14.

Non-randomised controlled trials: other study design

Ernst DS, MacDonald RN, Paterson AH, Jensen J, Brasher P, Bruera E. A double-blind, crossover trial of intravenous clodronate in metastatic bone pain. *J Pain Symptom Manage* 1992;**7**:4–11.

Lipton A, Glover D, Harvey H, Grabelsky S, Zelenakas K, Macerata R, *et al.* Pamidronate in the treatment of bone metastases: results of 2 dose-ranging trials in patients with breast or prostate cancer. *Ann Oncol* 1994;**5**(Suppl. 7):31–5.

Bayouth JE, Macey DJ, Kasi LP, Fossella FV. Dosimetry and toxicity of samarium-153-EDTMP administered for bone pain due to skeletal metastases. *J Nucl Med* 1994;**35**:63–9.

Pelliniemi TT, Irjala K, Mattila K, Pulkki K, Rajamaki A, Tienhaara A, *et al.* Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Finnish Leukaemia Group. *Blood* 1995;**85**:765–71.

Phillips KA, Urch M, Bishop JF. Radiation-recall dermatitis in a patient treated with paclitaxel. *J Clin Oncol* 1995;**13**:305.

Seaman E, Goluboff ET, Ross S, Sawczuk IS. Association of radionuclide bone scan and serum alkaline phosphatase in patients with metastatic renal cell carcinoma. *Urology* 1996;**48**:692–5.

Fernandez-Conde M, Alcover J, Aaron JE, Ordi J, Carretero P. Skeletal response to clodronate in prostate cancer with bone metastases. *Am J Clin Oncol* 1997;**20**:471–6.

Kraj M, Poglod R, Maj S, Pawlikowski J, Sokolowska U, Szczepanik J. [Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single centre experience).] *Acta Pol Pharm* 2002;**59**:478–82.

Berenson JR, Hillner BE, Kyle RA, Anderson K, Lipton A, Yee GC, *et al.* American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. *J Clin Oncol* 2002;**20**:3719–36.

Maxwell C, Swift R, Goode M, Doane L, Rogers M. Advances in supportive care of patients with cancer and bone metastases: nursing implications of zoledronic acid. *Clin J Oncol Nurs* 2003;**7**:403–8.

Plunkett TA, Rubens RD. Bisphosphonate therapy for patients with breast carcinoma: who to treat and when to stop. *Cancer* 2003;**97**:854–8.

Lipton A. Bisphosphonates and metastatic breast carcinoma. *Cancer* 2003;**97**:848–53.

Hirsh V, Tchekmedyian NS, Rosen LS, Zheng M, Hei YJ. Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumours: analysis based on history of skeletal complications. *Clin Lung Cancer* 2004;**6**:170–4.

Chern B, Joseph D, Joshua D, Pittman K, Richardson G, Schou M, *et al.* Bisphosphonate infusions: patient preference, safety and clinic use. *Support Care Cancer* 2004;**12**:463–6.

Chen BE, Cook RJ. Tests for multivariate recurrent events in the presence of a terminal event. *Biostatistics* 2004;**5**:129–43.

Leyland-Jones B. Pharmacokinetic and clinical equivalence of oral and intravenous ibandronate for metastatic bone disease. *Eur J Cancer Suppl* 2004;**2**:9–12.

Coleman RE, Major P, Lipton A, Brown JE, Lee K-A, Smith M, *et al*. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. *J Clin Oncol* 2005;**23**:4925–35.

Shakespeare TP, Thiagarajan A, GebSKI V. Evaluation of the quality of radiotherapy randomised trials for painful bone metastases: implications for future research design and reporting. *Cancer* 2005;**103**:1976–81.

Liepe K, Runge R, Kotzerke J. Systemic radionuclide therapy in pain palliation. *Am J Hosp Palliat Care* 2005;**22**:457–64.

Carteni G, Bordonaro R, Giotta F, Lorusso V, Scalone S, Vinaccia V, *et al*. Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial. *Oncologist* 2006;**11**:841–8.

Lein M, Wirth M, Miller K, Eickenberg HU, Weissbach L, Schmidt K, *et al*. Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic acid for detection of bone metastases progression. *Eur Urol* 2007;**52**:1381–7.

Major PP, Cook RJ, Lipton A, Smith MR, Terpos E, Coleman RE. Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity. *BMC Cancer* 2009;**9**:272.

Sharma K, Mohanti BK, Rath GK, Bhatnagar S. Pattern of palliative care, pain management and referral trends in patients receiving radiotherapy at a tertiary cancer centre. *Indian J Palliat Care* 2009;**15**:148–54.

Body JJ, Lipton A, Gralow J, Steger GG, Gao G, Yeh H, *et al*. Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure. *J Bone Min Res* 2010;**25**:440–6.

Treatment of hypercalcaemia

Gucalp R, Ritch P, Wiernik PH, Sarma PR, Keller A, Richman SP, *et al*. Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia. *J Clin Oncol* 1992;**10**:134–42.

Purohit OP, Radstone CR, Anthony C, Kanis JA, Coleman RE. A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy. *Br J Cancer* 1995;**72**:1289–93.